STAAR Surgical Company Sees FY24 Adjusted EBITDA Of ~$36M And Adjusted EBITDA Per Diluted Share Of ~$0.70
Portfolio Pulse from Benzinga Newsdesk
STAAR Surgical Company projects its FY24 financial outlook with net sales expected to be between $335 million to $340 million, and an Adjusted EBITDA of approximately $36 million. Adjusted EBITDA per diluted share is anticipated to be around $0.70. The forecast includes a 7% growth in EVO ICL sales in the APAC region, with a 10% increase in China, a 10% growth in the Americas including the U.S., and EMEA sales remaining steady with the previous fiscal year.
February 26, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
STAAR Surgical Company anticipates FY24 net sales between $335M-$340M, Adjusted EBITDA of ~$36M, and Adjusted EBITDA per diluted share of ~$0.70, with significant sales growth in APAC and the Americas.
STAAR Surgical's positive financial outlook for FY24, including expected sales growth in key regions and an increase in Adjusted EBITDA, is likely to be viewed favorably by investors. The detailed growth projections, especially in the APAC region and the Americas, suggest a strong market demand for their EVO ICL products. This positive outlook could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100